Ligand validation:7HR5

EVE: 1H-benzimidazole-2-sulfonamide

EVE is a Ligand Of Interest in 7HR5 designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
7HR5_EVE_B_402	100%	30%	0.045	0.985	1.63	1.17	1	2	3	0	100%	0.81
7HR5_EVE_B_401	98%	42%	0.053	0.973	1.17	1.09	1	2	1	0	100%	0.81
7HR5_EVE_A_402	98%	30%	0.057	0.975	1.6	1.18	1	2	3	0	100%	0.81
7HR5_EVE_A_403	97%	37%	0.062	0.979	1.38	1.1	1	2	0	0	100%	0.78
7HR5_EVE_B_403	96%	40%	0.067	0.975	1.28	1.07	1	2	1	0	100%	0.81
7HR5_EVE_A_401	96%	42%	0.061	0.968	1.16	1.09	1	1	4	0	100%	0.78
7HQU_EVE_B_401	96%	37%	0.065	0.974	1.36	1.1	1	1	2	0	100%	0.79
3S72_EVE_B_1	98%	3%	0.06	0.985	3.5	2.6	1	6	0	0	100%	1
5RTC_EVE_A_201	58%	5%	0.112	0.889	3.08	2.21	8	5	0	0	100%	0.7

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.